Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation

• Published in: Clinical therapeutics 1995-03, Vol.17 (2), p.241-251
• Main Authors: Kosoglou, Teddy, Patrick, James E., Cohen, Albert, Radwanski, Elaine, Christopher, David, Affrime, Melton B.
• Format: Article
• Language: English
• Subjects: Administration, Oral; Adult; Antianginal agents. Coronary vasodilator agents; Biological and medical sciences; Biological Availability; Cardiovascular system; Cross-Over Studies; Delayed-Action Preparations; Drug Administration Schedule; Half-Life; Humans; Isosorbide Dinitrate - adverse effects; Isosorbide Dinitrate - analogs & derivatives; Isosorbide Dinitrate - blood; Isosorbide Dinitrate - pharmacokinetics; Male; Medical sciences; Pharmacology. Drug treatments; Vasodilator Agents - adverse effects; Vasodilator Agents - blood; Vasodilator Agents - pharmacokinetics
• ISSN: 0149-2918; 1879-114X
• DOI: 10.1016/0149-2918(95)80022-0

The steady-state pharmacokinetic profile of isosorbide-5-mononitrate (5-ISMN) after oral administration of an extended-release tablet formulation of 5-ISMN 60 mg or 120 mg once a day was compared with that after administration of isosorbide dinitrate (ISDN) 40 mg every 6 hours, in a randomized, open-label, three-way crossover trial in 24 healthy men. After oral administration of extended-release 5-ISMN 60 mg or 120 mg once daily, 5-ISMN was slowly absorbed, reaching mean peak plasma concentrations of 557 and 1151 ng/mL, respectively, in approximately 3 hours. Plasma concentrations of 5-ISMN were dose proportional between 60 mg and 120 mg. After oral administration of ISDN 40 mg every 6 hours, a mean peak plasma 5-ISMN concentration of 806 ng/mL was achieved in less than 2 hours (mean time to reach the maximum plasma concentration was 1.5 hours). The mean plasma apparent elimination half-life of 5-ISMN was 6.2 hours after extended-release 5-ISMN administration and 7.1 hours after ISDN. Although the maximum plasma concentration was higher and the minimum plasma concentration was lower after administration of extended-release 5-ISMN 120 mg once daily compared with ISDN 40 mg every 6 hours, there was no significant difference ( P > 0.05) in the “bioavailability” of 5-ISMN between these two treatments. The most commonly reported adverse events in these “nitrate-naive” subjects were headache, dizziness, nausea, and vomiting; these were dose related and their incidence decreased with repeated exposure.